{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:29:47Z","timestamp":1793179787823,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Deleterious germ line RUNX1 variants cause familial platelet disorder with associated myeloid malignancy (FPDMM), characterized by thrombocytopenia, platelet dysfunction, and predisposition to hematologic malignancies (HM). We examined clinical and laboratory findings of pediatric (&amp;lt;19 years) patients with RUNX1-FPDMM enrolled in the National Institutes of Health RUNX1 Natural History Study. Pediatric patients have thrombocytopenia (131 \u00b1 49 \u00d7103\/\u03bcL vs 314 \u00b1 55 \u00d7103\/\u03bcL) and mild eosinophilia (372 \u00b1 244\/\u03bcL vs 165 \u00b1 100\/\u03bcL) similar to adults. Abnormal bleeding is less frequent in children than adults (32% vs 42%). Of 213 patients with RUNX1-FPDMM, 31 developed HM (13 pediatric, 19 adult; 1 had second malignancy). Lifetime HM risk is 42% (26%-55%). Median age of HM diagnosis is 36 years (range, 1-74). Pediatric patients have a 7.3% (3.5%-11%) cumulative incidence by age 18 years, 57.7-fold (27.7-86.6) higher than the general population, and are 3.4-fold more likely to develop HM by age 5 years than patients with Fanconi anemia. Unlike adult patients whose HM were all myeloid, pediatric patients develop a spectrum of HM but with a myeloid excess compared with the general pediatric population (62% vs 24%). Pediatric RUNX1-FPDMM HM is less likely than adult to have multiple somatic mutations (22% vs 67%), but more likely to have chromosome changes (67% vs 47%). We recommend prompt, universal cascade RUNX1 testing following a new diagnosis, regardless of age. Upon diagnosis, management of pediatric RUNX1-FPDMM should include a baseline bone marrow biopsy, once clinically acceptable, and peripheral blood evaluations. We recommend routine monitoring with quarterly blood counts and annual biopsy to monitor for changes and HM transformation. This trial was registered www.clinicaltrials.gov as #NCT03854318.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017808","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T21:25:46Z","timestamp":1769808346000},"page":"3075-3085","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Hematologic malignancies in pediatric patients with\n                    <i>RUNX1<\/i>\n                    -familial platelet disorder with associated myeloid malignancy"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8685-4230","authenticated-orcid":false,"given":"Amra","family":"Kajdic","sequence":"first","affiliation":[{"name":"1Oncogenesis and Development Section, Translational and Functional Genomics Branch, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-1162","authenticated-orcid":false,"given":"Natalie T.","family":"Deuitch","sequence":"additional","affiliation":[{"name":"1Oncogenesis and Development Section, Translational and Functional Genomics Branch, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Bresciani","sequence":"additional","affiliation":[{"name":"1Oncogenesis and Development Section, Translational and Functional Genomics Branch, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Chong","sequence":"additional","affiliation":[{"name":"1Oncogenesis and Development Section, Translational and Functional Genomics Branch, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Craft","sequence":"additional","affiliation":[{"name":"1Oncogenesis and Development Section, Translational and Functional Genomics Branch, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-7440","authenticated-orcid":false,"given":"Michelly K.","family":"Sampaio de Melo","sequence":"additional","affiliation":[{"name":"2Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joie","family":"Davis","sequence":"additional","affiliation":[{"name":"1Oncogenesis and Development Section, Translational and Functional Genomics Branch, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roa","family":"Bashtawi","sequence":"additional","affiliation":[{"name":"3Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Patel","sequence":"additional","affiliation":[{"name":"2Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-1453","authenticated-orcid":false,"given":"Lisa J.","family":"McReynolds","sequence":"additional","affiliation":[{"name":"3Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-1863","authenticated-orcid":false,"given":"Neelam","family":"Giri","sequence":"additional","affiliation":[{"name":"3Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-4191","authenticated-orcid":false,"given":"Katherine R.","family":"Calvo","sequence":"additional","affiliation":[{"name":"2Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-8568","authenticated-orcid":false,"given":"David J.","family":"Young","sequence":"additional","affiliation":[{"name":"4Translational Stem Cell Biology Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6779-025X","authenticated-orcid":false,"given":"Paul P.","family":"Liu","sequence":"additional","affiliation":[{"name":"1Oncogenesis and Development Section, Translational and Functional Genomics Branch, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"2","key":"2026051211563005500_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/13793","article-title":"Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia","volume":"23","author":"Song","year":"1999","journal-title":"Nat Genet"},{"issue":"25","key":"2026051211563005500_bib2","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.2023019746","article-title":"Natural history study of patients with familial platelet disorder with associated myeloid malignancy","volume":"142","author":"Cunningham","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026051211563005500_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/bloodadvances.2023011165","article-title":"Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy","volume":"8","author":"Yu","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026051211563005500_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2019000937","article-title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)","volume":"136","author":"Brown","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026051211563005500_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1042819031000139611","article-title":"Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia","volume":"45","author":"Ganly","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026051211563005500_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/nyas.12346","article-title":"Familial myelodysplastic syndrome\/acute leukemia syndromes: a review and utility for translational investigations","volume":"1310","author":"West","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2026051211563005500_bib7","doi-asserted-by":"crossref","first-page":"e70057","DOI":"10.1002\/hem3.70057","article-title":"Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (familial platelet disorder with associated myeloid malignancy)","volume":"9","author":"Ernst","year":"2025","journal-title":"Hemasphere"},{"issue":"11","key":"2026051211563005500_bib8","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3324\/haematol.2021.278762","article-title":"The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy","volume":"106","author":"Homan","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2026051211563005500_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jha2.594","article-title":"Germline RUNX1 variants in paediatric patients in a French specialised centre","volume":"4","author":"Liu","year":"2023","journal-title":"EJHaem"},{"issue":"5","key":"2026051211563005500_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"16","key":"2026051211563005500_bib11","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/bloodadvances.2022008017","article-title":"Revision of RUNX1 variant curation rules","volume":"6","author":"Feurstein","year":"2022","journal-title":"Blood Adv"},{"key":"2026051211563005500_bib12","author":"Edward","year":"2021","edition":"8th ed"},{"issue":"7","key":"2026051211563005500_bib13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/jth.14454","article-title":"Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders","volume":"17","author":"Adler","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026051211563005500_bib14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/jth.15263","article-title":"The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: communication from the ISTH SSC Subcommittee on Platelet Physiology","volume":"19","author":"Gresele","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2026051211563005500_bib15","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Incidence - SEER Research Limited-Field Data, 22 Registries, November 2023 Submission (2000-2021). Accessed 1 February 2025. https:\/\/seer.cancer.gov\/."},{"issue":"1","key":"2026051211563005500_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2017.178111","article-title":"Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up","volume":"103","author":"Alter","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"2026051211563005500_bib17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026051211563005500_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2026051211563005500_bib19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","article-title":"RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv"},{"issue":"20","key":"2026051211563005500_bib20","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1182\/bloodadvances.2023010045","article-title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41","volume":"7","author":"Homan","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026051211563005500_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"7696","key":"2026051211563005500_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Grobner","year":"2018","journal-title":"Nature"},{"key":"2026051211563005500_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/EDBK_160621","article-title":"The advantages and challenges of testing children for heritable predisposition to cancer","volume":"35","author":"Kesserwan","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"2026051211563005500_bib24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/bjh.19989","article-title":"Genetic testing to identify hereditary predispositions to haematological malignancy is critical prior to allogenic haematopoietic cell transplant","volume":"206","author":"Kajdic","year":"2025","journal-title":"Br J Haematol"},{"issue":"2","key":"2026051211563005500_bib25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bjh.20194","article-title":"Pregnancy and delivery outcomes in individuals with RUNX1-Familial Platelet Disorder","volume":"207","author":"Deuitch","year":"2025","journal-title":"Br J Haematol"},{"issue":"10","key":"2026051211563005500_bib26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMp1700196","article-title":"Anesthesia and developing brains - implications of the FDA warning","volume":"376","author":"Andropoulos","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026051211563005500_bib27","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/ALN.0000000000004116","article-title":"Anesthesia and developing brains: unanswered questions and proposed paths forward","volume":"136","author":"Ing","year":"2022","journal-title":"Anesthesiology"},{"issue":"10","key":"2026051211563005500_bib28","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3324\/haematol.2017.167726","article-title":"Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation","volume":"102","author":"Kanagal-Shamanna","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2026051211563005500_bib29","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.bneo.2024.100026","article-title":"Correlation between peripheral blood and bone marrow mutations among patients with MDS from the national MDS study","volume":"1","author":"DeZern","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"7","key":"2026051211563005500_bib30","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/s41375-024-02297-5","article-title":"Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients","volume":"38","author":"Huber","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"2026051211563005500_bib31","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3390\/cancers15082305","article-title":"Myeloid NGS analyses of paired samples from bone marrow and peripheral blood yield concordant results: a prospective cohort analysis of the AGMT Study Group","volume":"15","author":"Jansko-Gadermeir","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2026051211563005500_bib32","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/bloodadvances.2020002306","article-title":"Mutational analysis of hematologic neoplasms in 164 paired peripheral blood and bone marrow samples by next-generation sequencing","volume":"4","author":"Lucas","year":"2020","journal-title":"Blood Adv"},{"key":"2026051211563005500_bib33","doi-asserted-by":"crossref","first-page":"8091746","DOI":"10.1155\/2022\/8091746","article-title":"Concordance of peripheral blood and bone marrow next-generation sequencing in hematologic neoplasms","volume":"2022","author":"Jumniensuk","year":"2022","journal-title":"Adv Hematol"},{"issue":"4","key":"2026051211563005500_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/2040620713487399","article-title":"Recognizing familial myeloid leukemia in adults","volume":"4","author":"Nickels","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"2026051211563005500_bib35","first-page":"43","volume-title":"Fanconi Anemia: Guidelines for Diagnosis and Management","author":"Alter","year":"2014;4"},{"issue":"24","key":"2026051211563005500_bib36","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-01-583625","article-title":"How I treat MDS and AML in Fanconi anemia","volume":"127","author":"Peffault de Latour","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026051211563005500_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.2022017717","article-title":"Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management","volume":"145","author":"Sahoo","year":"2025","journal-title":"Blood"},{"issue":"23","key":"2026051211563005500_bib38","first-page":"2853","article-title":"The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia","volume":"141","author":"Hakkarainen","year":"2023","journal-title":"Blood"},{"key":"2026051211563005500_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2011.06349.x","article-title":"Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome","volume":"1242","author":"Dror","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2026051211563005500_bib40","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2352-3026(19)30206-6","article-title":"Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study","volume":"7","author":"Myers","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026051211563005500_bib41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00277-023-05128-2","article-title":"ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution","volume":"102","author":"Baccelli","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"2026051211563005500_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.blre.2010.03.002","article-title":"Pathophysiology and management of inherited bone marrow failure syndromes","volume":"24","author":"Shimamura","year":"2010","journal-title":"Blood Rev"},{"issue":"1","key":"2026051211563005500_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.18682","article-title":"Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT)","volume":"201","author":"Clark","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"2026051211563005500_bib44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"2026051211563005500_bib45","doi-asserted-by":"crossref","first-page":"107483","DOI":"10.1016\/j.leukres.2024.107483","article-title":"Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: data from a real-world study","volume":"139","author":"Wan","year":"2024","journal-title":"Leuk Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3075\/2516215\/blooda_adv-2025-017808-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3075\/2516215\/blooda_adv-2025-017808-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:56:50Z","timestamp":1778601410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3075\/566370\/Hematologic-malignancies-in-pediatric-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017808","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,1]]}}}